Trial Profile
A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged ≥ 6 to <18 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Abacavir; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Lamivudine/tenofovir-disoproxil-fumarate; Lamivudine/zidovudine
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms PAINT
- Sponsors Janssen R&D Ireland; Janssen Sciences Ireland UC
- 28 Jul 2023 According to Janssen media release, the company announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of EDURANT (rilpivirine) to include the treatment of HIV-1 infection in children weighing 10 kg or more. A parallel Marketing Authorization application has also been submitted to the European Medicines Agency (EMA) in support of a type II variation and line extension for expanded pediatric use in Europe.
- 24 Nov 2022 Status changed from active, no longer recruiting to completed.
- 09 Jun 2022 Planned End Date changed from 1 Sep 2022 to 8 Sep 2022.